Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02836574 · ClinicalTrials.gov registry record · Phase 2
A Study of Renal Autologous Cell Therapy (REACT) in Type 2 Diabetics With Chronic Kidney Disease
A Phase 2 study of Type 2 Diabetes Mellitus and Chronic Kidney Disease, sponsored by Prokidney.
- Completed
- Registry status
- Phase 2
- Development phase
- 83
- Enrollment target
- 16
- Study locations
NCT02836574: Completed Phase 2 study of Type 2 Diabetes Mellitus and Chronic Kidney Disease, sponsored by Prokidney.
NCT02836574 is a Phase 2 study of Type 2 Diabetes Mellitus and Chronic Kidney Disease that has completed, run by Prokidney. The registered enrollment target is 83 participants, below the 2,959-participant average among 130 other Type 2 Diabetes Mellitus trials with a reported enrollment target (97% lower). The trial reports 16 study locations across 15 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02836574, a Phase 2 study of Type 2 Diabetes Mellitus and Chronic Kidney Disease, has completed, sponsored by Prokidney.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 83 participants
- Enrollment target
- 16
- Study locations
Study Summary
To assess the safety and efficacy of up to two REACT injections given 6 months (+4 weeks) apart and delivered into the biopsied kidney using a percutaneous approach in participants with Type 2 Diabetes Mellitus (T2DM) and Chronic Kidney Disease (CKD).
Primary Outcome
Serial measurements of estimated glomerular filtration rate (eGFR) obtained pre-randomization and at three-month intervals through 24 months after the last REACT injection in the active treatment group and at least 12 months post last REACT injection in the deferred treatment group.
Conditions Studied
Interventions
- BIOLOGICAL Renal Autologous Cell Therapy (REACT)
- PROCEDURE Renal Biopsy
Study Locations (16)
Michigan
- University of Michigan - Ann Arbor
- Paragon Health - Kalamazoo
Arizona
- University of Arizona - Tucson
Colorado
- Kidney Associates of Colorado - Denver
Connecticut
- Yale Univeristy - New Haven
Florida
- University of Florida - Gainesville
Idaho
- Boise Kidney and Hypertension Institute - Meridian
Illinois
- University of Chicago Medical Center - Chicago
Kentucky
- University of Louisville - Louisville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 83 participants |
| Start Date | 2016-09 |
| Est. Completion | 2023-12 |
| Phase | Phase 2 |
What the finished NCT02836574 record still lists
NCT02836574 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 83 participants, a relatively small participant target, below the 2,959-participant average among 130 other Type 2 Diabetes Mellitus trials with a reported enrollment target (97% lower).
The record links to 2 conditions, with Type 2 Diabetes Mellitus appearing as the primary indexed condition, and to 2 interventions - of which Renal Autologous Cell Therapy (REACT) is the first listed.
NCT02836574 lists 16 locations in 15 states (Michigan, Arizona, Colorado).
Frequently Asked Questions
What is clinical trial NCT02836574 about?
NCT02836574 is a clinical study titled "A Study of Renal Autologous Cell Therapy (REACT) in Type 2 Diabetics With Chronic Kidney Disease". To assess the safety and efficacy of up to two REACT injections given 6 months (+4 weeks) apart and delivered into the biopsied kidney using a percutaneous approach in participants with Type 2 Diabetes Mellitus (T2DM) and Chronic Kidney Disease (CKD).
What is the current status of trial NCT02836574?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 83 participants. The study started on 2016-09. Estimated completion is 2023-12.
What conditions does trial NCT02836574 study?
This clinical trial studies the following conditions: Type 2 Diabetes Mellitus, Chronic Kidney Disease.
What interventions are being tested in trial NCT02836574?
The interventions under investigation include: Renal Autologous Cell Therapy (REACT) (BIOLOGICAL), Renal Biopsy (PROCEDURE).
Who is sponsoring clinical trial NCT02836574?
This trial is sponsored by Prokidney, which has 8 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02836574 being conducted?
This trial has 16 study locations across Arizona, Colorado, Connecticut, Florida, Idaho. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Type 2 Diabetes Mellitus
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02836574's enrollment target sits among peer trials
83 63rd of 130 higher than 68 of 130 other Type 2 Diabetes Mellitus trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Type 2 Diabetes Mellitus trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Compare Different Doses of RO7795081 With a Placebo or Semaglutide in People With Type 2 Diabetes
RECRUITING · Phase 2
-
Semaglutide Effects in Obese Youth With Prediabetes/New Onset Type 2 Diabetes and Non-Alcoholic Fatty Liver Disease
RECRUITING · Phase 2
-
Regulation of Endogenous Glucose Production by Central KATP Channels
RECRUITING · Phase 2
-
Signaling Mechanisms and Vascular Function in Patients With Diabetes Mellitus
COMPLETED · Phase 2
-
The Effect of Bariatric Surgery on Metabolism, the Metabolome and Microbiome in Patients With Type 2 Diabetes
COMPLETED · Phase 2
-
A Study to Evaluate Safety and Efficacy of TTP054 for 12 Weeks in Subjects With Type 2 Diabetes
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02974647 · 83 participants · Phase 2
Study of Ruxolitinib in Relapsed or Refractory T or NK Cell Lymphoma
- NCT03919292 · 83 participants · Phase 1
Neratinib + Valproate in Advanced Solid Tumors, w/Expansion Cohort in Ras-Mutated Ca
- NCT04626674 · 83 participants · Phase 1
A Gene Transfer Therapy Study to Evaluate the Safety of and Expression From Delandistrogene Moxeparvovec (SRP-9001) in Participants With Duchenne Muscular Dystrophy (DMD)
- NCT05277168 · 83 participants · Phase 1
A Trial TO Evaluate THE Safety, Tolerability, Pharmacokinetics, AND Efficacy OF Shr-a1904 IN Subjects With Advanced Solid Tumors
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia